Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Hepatitis C 2Carcinoma, Hepatocellular 2

Interventions

Ribavirin 5ledipasvir, sofosbuvir drug combination 3sofosbuvir-velpatasvir drug combination 2elbasvir-grazoprevir drug combination 2Sorafenib 2Sofosbuvir 2Chromatography, High Pressure Liquid 2tremelimumab 1telaprevir 1rocakinogene sifuplasmid 1pembrolizumab 1peginterferon alfa-2a 1navitoclax 1menatetrenone 1ledipasvir 1hepatitis C immune globulin, human 1grazoprevir 1elbasvir 1Rapid Diagnostic Tests 1Raltegravir Potassium 1Patient Navigation 1Medical Marijuana 1Mass Screening 1Introns 1Infliximab 1Immunoglobulin G 1Immunoenzyme Techniques 1Hypothermia, Induced 1Enzyme-Linked Immunosorbent Assay 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hepatitis C × elbasvir-grazoprevir drug combination × Clear all
NCT02940496 2025-07-15

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

M.D. Anderson Cancer Center

Phase 2 Completed
15 enrolled 8 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular

NCT04546802 2020-09-14

HATCHeT

Bayside Health

Phase 3 Withdrawn
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡